Pliant Therapeutics Inc Aktie News

SOUTH SAN FRANCISCO, Calif., 18. Aug. 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) gab heute den Erhalt der Fast-Track-Zulassung durch die U.S. Food and Drug Administration (FDA) für PLN-101095 bekannt, ein oral verabreichbares, kleines Molekül und dual selektiver Inhibitor der Integrine αvβ8 und αvβ1, in Kombination mit Pembrolizumab für die potenzielle Behandlung von soli...

FORTIFY, eine Phase‑1b‑Indikationserweiterungsstudie zu PLN‑101095, verzeichnet starke Einschreibungen Ernannte die erfahrenen Leiter der Onkologie‑Arzneimittelentwicklung Flavia Borellini, Ph.D. und Robert Iannone, M.D.

Die Ernennungen bringen globale Erfahrung in der onkologischen Arzneimittelentwicklung und vertiefen die operative sowie regulatorische Expertise des Vorstands

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095  enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2...

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, and Keit...

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, smal...

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months